Lys25
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Acetylation Site Page:
Lys25 - ACAA2 (human)

Site Information
GAYGGLLkDFTATDL    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: ACAA2 (mouse): K25
Blast this site against: NCBI  SwissProt  PDB 

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
Disease tissue studied: liver cancer (12, 13), hepatocellular carcinoma (12, 13)
Relevant cell line - cell type - tissue: A549 (pulmonary) (2), HepG2 (hepatic) (12, 13), Jurkat (T lymphocyte) (2), liver (1), OCI-ly3 (B lymphocyte) (6, 8, 10, 11), RC-K8 (B lymphocyte) (7, 9), Reh (B lymphocyte) (3, 4, 5)




References

1

Zhao S, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-4
20167786   Curated Info

2

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

3

(2007) CST Curation Set: 2707; Year: 2007; Biosample: Reh; Disease: acute lymphocytic leukemia; Treatment: DMSO; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

4

(2007) CST Curation Set: 2708; Year: 2007; Biosample: Reh; Disease: acute lymphocytic leukemia; Treatment: SAHA 3h; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

5

(2007) CST Curation Set: 2709; Year: 2007; Biosample: Reh; Disease: acute lymphocytic leukemia; Treatment: SAHA 6h; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

6

(2007) CST Curation Set: 2510; Year: 2007; Biosample: OCI-ly3; Disease: B cell lymphoma; Treatment: DMSO; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

7

(2007) CST Curation Set: 2436; Year: 2007; Biosample: RC-K8; Disease: B cell lymphoma; Treatment: DMSO; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

8

(2007) CST Curation Set: 2437; Year: 2007; Biosample: OCI-ly3; Disease: B cell lymphoma; Treatment: DMSO; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

9

(2007) CST Curation Set: 2438; Year: 2007; Biosample: RC-K8; Disease: B cell lymphoma; Treatment: SAHA 3h; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

10

(2007) CST Curation Set: 2440; Year: 2007; Biosample: OCI-ly3; Disease: B cell lymphoma; Treatment: SAHA 3h; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

11

(2007) CST Curation Set: 2441; Year: 2007; Biosample: OCI-ly3; Disease: B cell lymphoma; Treatment: SAHA 6h; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

12

(2005) CST Curation Set: 868; Year: 2005; Biosample: HepG2; Disease: hepatocellular carcinoma; Treatment: TSA; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

13

(2005) CST Curation Set: 869; Year: 2005; Biosample: HepG2; Disease: hepatocellular carcinoma; Treatment: TSA; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-AcK
Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.